Trial Profile
A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Pyy 336 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Gila Therapeutics
- 12 Apr 2018 New trial record